JA
Jagsonpal Pharmaceuticals Limited
JAGSNPHARM.BO · BSE
₹243.00 +0.16% (+₹0.40)
1M +3.63%
Market Cap ₹16.0B
P/E Ratio 35.18x
Div. Yield -
ROE 17.19%
Bulios Fair Price
₹216.27
11.0% downside
Current Price
₹243
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JAGSNPHARM.BO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
13 /100
Expensive P/E 35.18x
EV/EBITDA 23.46x
P/FCF 65.09x
Growth
59 /100
Stable EPS growth 15.64%
Rev. growth 6.66%
Book val. growth 20.23%
Profitability
77 /100
Strong Gross margin 55.42%
Net margin 15.48%
FCF margin 8.36%
Quality
80 /100
Excellent ROE 17.19%
ROIC N/A
ROA N/A
Debt
100 /100
Low Debt/Equity 0.00x
Int. coverage 57.52x
Net debt/EBITDA 0.00x
Stability
44 /100
Moderate Beta -0.28x
Rev. volatility 20.32%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JAGSNPHARM.BO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Manish Gupta
Employees
1,297
Headquarters
Gurugram